Nickel sensitivity as a complication of squaric acid dibutylester treatment of alopecia areata

Valsecchi, R.; Cainelli, T.

doi:10.1111/j.1600-0536.1985.tb01123.x

Cited by 2 publications

(1 citation statement)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Except for the expected adverse reactions, that is, contact dermatitis [148,[163][164][165] or lymphadenopathy [166][167][168], there are some rare or even serious adverse events reported. These include urticaria [169][170][171][172][173][174][175][176][177], depigmentation [155,156,160], vitiligo [150-154, 157-159, 178], erythema multiforme [179][180][181][182][183], discoid lupus erythematosus [184,185], angioedema [186,187], nickel sensitivity [188], allergic contact dermatitis from dyes in wigs [189], acquired hair curling [190], hair pigmentary changes [191], psoriatic koebnerization [192], pityriasis lichenoides [193], dyspepsia [173], epidermolysis bullosa acquisita [194], and anaphylaxis [195]. In addition, there are a few reports documenting sensitization to the medical staff that handle the chemical compound [196][197][198][199][200][201].…”

Section: Adverse Effects and Safety Concerns Of Topical Immunotherapymentioning

confidence: 99%

Use of Contact Immunotherapy in the Treatment of Skin Diseases Other than Alopecia Areata

Lai

Tsai

2022

Dermatol Ther (Heidelb)

View full text Add to dashboard Cite

For decades, contact immunotherapy with dinitrochlorobenzene, diphencyprone, and squaric acid dibutylester has played an important role in both clinical practice and scientific research. It is listed as the first-line treatment for extensive alopecia areata and was more recently approved for melanoma treatment as an orphan drug in the USA. Moreover, owing to the relative low cost and safety, topical immunotherapy has also been used in many infectious, neoplastic, and inflammatory dermatological diseases. It is especially valuable in vulnerable groups, for cosmetic/pain sensitive areas, or for multiple lesions. In this review, we summarize the current evidence supporting the use of contact immunotherapy for treatment of skin diseases, from articles collected from PubMed database. Owing to space limitation and already numerous studies focusing on alopecia areata, we include only skin diseases other than alopecia areata. In addition to diseases that have been reported to be treated by contact immunotherapy, the hypothesized mechanism, prognosis prediction, efficacy, and safety of these topical agents are discussed.

show abstract

Section: Adverse Effects and Safety Concerns Of Topical Immunotherapymentioning

confidence: 99%

Use of Contact Immunotherapy in the Treatment of Skin Diseases Other than Alopecia Areata

Lai

Tsai

2022

Dermatol Ther (Heidelb)

View full text Add to dashboard Cite

show abstract

Topical contact allergens

Lin¹

2013

Comprehensive Dermatologic Drug Therapy

View full text Add to dashboard Cite

Nickel sensitivity as a complication of squaric acid dibutylester treatment of alopecia areata

Cited by 2 publications

References 6 publications

Use of Contact Immunotherapy in the Treatment of Skin Diseases Other than Alopecia Areata

Use of Contact Immunotherapy in the Treatment of Skin Diseases Other than Alopecia Areata

Topical contact allergens

Contact Info

Product

Resources

About